Nasus Pharma (NSRX) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Technology and product overview

• Proprietary powder-based intranasal technology enables rapid and reliable drug delivery by optimizing particle size and shape for deep nasal absorption.

• Lead product, NS002, is a needle-free intranasal epinephrine powder for anaphylaxis, showing superior absorption compared to EpiPen in clinical studies.

• Powder formulation offers advantages over liquid products, including longer shelf life, compact size, and ease of use.

Clinical development and pipeline

• NS002 is advancing to a pivotal clinical study in Q4 2024, with data expected in Q1 2027 and NDA submission planned for mid-2027.

• Additional pipeline includes ondansetron for chemotherapy-induced nausea (first-in-human in H2 2026) and two undisclosed products in metabolic and cardiovascular areas.

• By end of 2026, two to three products are expected in clinical trials, all leveraging the powder intranasal platform.

Market opportunity and competitive landscape

• Anaphylaxis market is valued at $2.5 billion and growing, with significant unmet need due to needle phobia and low EpiPen adherence.

• Only one-third of at-risk U.S. patients have an EpiPen prescription; needle-free alternatives represent a major growth opportunity.

• Competitors include ARS Pharmaceuticals (liquid neffy) and Aquestive (sublingual), but NS002 demonstrates fastest onset and highest early absorption rates.